AXL, termed from the Greek word anexelekto, or uncontrolled, was identified initially as a transforming oncogene in two chronic myelogeneous leukemia (CML) patients in 1991 (23). Here, AXL is linked to chronic myelogenous leukemia, BCR-ABL1 positive.